Playback speed
10 seconds
This video is featured in the 2024 ESMO Annual Meeting Insights Hub
ESMO 2024 Insights: Stereotactic RT Alone or Followed by Niraparib for OMD or OPD in Ovarian Cancer Following PARPi Therapy - SOPRANO Trial
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Susana Banerjee
By
2024 ESMO Annual Meeting Insights Hub
FEATURING
Susana Banerjee
46 views
October 7, 2024
Comments 0
Login to view comments.
Click here to Login